{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:39:44Z","timestamp":1740152384960,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13104-017-2438-7","type":"journal-article","created":{"date-parts":[[2017,3,4]],"date-time":"2017-03-04T00:04:27Z","timestamp":1488585867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["An unexpected diagnosis of human immunodeficiency virus-2 infection in an overseas visitor: a case report"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1716-8518","authenticated-orcid":false,"given":"Asma","family":"Sohail","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyndal","family":"Van Leer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,4]]},"reference":[{"key":"2438_CR1","unstructured":"World Health Organisation. HIV\/AIDS. http:\/\/who.int\/hiv\/en . Accessed 30 Aug 2015."},{"issue":"6","key":"2438_CR2","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/cid\/ciq248","volume":"52","author":"OT Campbell-Yesufu","year":"2011","unstructured":"Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis. 2011;52(6):780\u20137.","journal-title":"Clin Infect Dis"},{"key":"2438_CR3","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1086\/315010","volume":"180","author":"S Popper","year":"1999","unstructured":"Popper S, Sarr A, Travers K, et al. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis. 1999;180:1116\u201321.","journal-title":"J Infect Dis"},{"issue":"1","key":"2438_CR4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1473-3099(10)70186-9","volume":"11","author":"DM Tebit","year":"2011","unstructured":"Tebit DM, Arts EJ. Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Lancet Infect Dis. 2011;11(1):45\u201356.","journal-title":"Lancet Infect Dis"},{"key":"2438_CR5","unstructured":"Australasian Society for HIV. Viral hepatitis and sexual health. HIV-2 infection. http:\/\/arv.ashm.org.au\/arv-guidelines\/special-patient-populations\/hiv-2-infection . Accessed 31 Dec 2015."},{"key":"2438_CR6","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0140-6736(94)90065-5","volume":"343","author":"P Kanki","year":"1994","unstructured":"Kanki P, Travers K, Mboup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet. 1994;343:943\u20136.","journal-title":"Lancet"},{"key":"2438_CR7","unstructured":"Centers for Disease Control and Prevention. Laboratory testing for the diagnosis of HIV infection: updated recommendations. http:\/\/www.cdc.gov\/hiv\/pdf\/hivtestingalgorithmrecommendation-final.pdf . Accessed 31 Dec 2015."},{"key":"2438_CR8","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1747-0285.2008.00647.x","volume":"71","author":"ET Brower","year":"2008","unstructured":"Brower ET, Bacha UM, Kawasaki Y, Freire E. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des. 2008;71:298\u2013305.","journal-title":"Chem Biol Drug Des"},{"issue":"5","key":"2438_CR9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn335","volume":"62","author":"B Roquebert","year":"2008","unstructured":"Roquebert B, Damond F, Collin G, et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother. 2008;62(5):914\u201320.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"2438_CR10","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1468-1293.2010.00889.x","volume":"11","author":"Y Gilleece","year":"2010","unstructured":"Gilleece Y, Chadwick DR, Breuer J, et al. British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. HIV Med. 2010;11(10):611\u20139.","journal-title":"HIV Med."},{"key":"2438_CR11","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Considerations for antiretroviral use in special patient populations: HIV-2 infection. Department of Health and Human Services. http:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv-guidelines\/24\/hiv-2-infection . Accessed 31 Dec 2015."}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-017-2438-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,25]],"date-time":"2017-06-25T07:53:14Z","timestamp":1498377194000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-017-2438-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,4]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2438"],"URL":"https:\/\/doi.org\/10.1186\/s13104-017-2438-7","relation":{},"ISSN":["1756-0500"],"issn-type":[{"type":"electronic","value":"1756-0500"}],"subject":[],"published":{"date-parts":[[2017,3,4]]},"article-number":"116"}}